Melphalan works by interfering with the growth of harmful cells. Acting on the body at a cellular level, the therapy helps manage specific types of malignancy.
When chemotherapy is needed for certain cancers, doctors may choose a drug that works by interfering with cell growth. Melphalan belongs to a class of medicines called alkylating agents, which attach to DNA in rapidly dividing cells and help slow or stop their spread. Its primary therapeutic role is to assist with the treatment of specific blood-related cancers and some solid tumors. This active compound can be found in products such as Alkacel, which is available in Singapore.
Patients receiving Alkacel will encounter melphalan as the key component that provides the intended effect. The drug is offered in oral tablets and also in injectable forms for hospitals. In Singapore, the same ingredient may appear under different brand names or as a generic version, but the melphalan content remains consistent across these options. The choice between tablet and injection often depends on the treatment plan decided by the healthcare team.
People diagnosed with multiple myeloma, a cancer of the bone marrow, often receive melphalan as part of their regimen. It is also used for certain ovarian cancers and for some cases of chronic lymphocytic leukemia. In addition, melphalan may be chosen for patients with advanced solid tumors when other options are limited. Generally, adult patients whose disease shows sensitivity to alkylating agents are the ones who may be prescribed melphalan-containing therapies.
Melphalan works by attaching small chemical groups to the DNA inside cells that are dividing quickly, such as cancer cells. This attachment makes it harder for the cells to copy their genetic material, which can trigger the cells to stop growing or to die. Because normal cells divide more slowly, melphalan tends to affect cancer cells more noticeably, helping to control disease progression.
Mild nausea, occasional vomiting, and temporary loss of appetite are frequently reported after starting melphalan. Some patients notice a reduction in white blood cells, leading to a higher chance of mild infections that usually improve with time.
Rare but important warning signs include fever with chills, severe mouth sores, or unusually heavy bleeding. If any of these occur, urgent medical attention may be needed.
Melphalan should be avoided by individuals who are pregnant or planning to become pregnant, as it can affect fetal development. People with known hypersensitivity to melphalan or other alkylating agents, as well as those with severely weakened bone-marrow function, should not use this medication.
Alcohol can increase the risk of liver irritation while taking melphalan. Certain medicines that also suppress the immune system or affect blood clotting may interact, so the labeling of each specific product should be reviewed for detailed guidance.
Storing melphalan-containing products in a cool, dry place protects their stability, and tablets should be kept in their original container. Treatment courses can vary widely; some patients may use the drug for a few weeks, while others may receive it over several months, depending on the disease stage and the specific formulation of Alkacel. For detailed usage, dosing, and administration, refer to the specific medication's clinical information.
This article provides an educational overview of melphalan and is not a substitute for professional medical advice. Medicines containing this ingredient, such as Alkacel, may differ in formulation, strength, and directions for use. The information presented does not create any liability for clinical decision-making. Readers are encouraged to review the labeling of their specific medication and seek guidance from a qualified healthcare professional for personalized care.
Below are reliable sources for additional details about melphalan.
